Efficacy and safety of imatinib mesylate (Gleevec®) and immunohistochemical expression of c-Kit and PDGFR-β in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus

Gynecologic Oncology

Volumn 117, Issue 2, 2010, Pages 248-254

  Huh, Warner K ^a   Sill, Michael W ^b,c   Darcy, Kathleen M ^b   Elias, Kevin M ^d   Hoffman, James S ^e   Boggess, John F ^f   Alvarez, Ronald D ^a   Long, Harry J ^g   O'Malley, David M ^h   Birrer, Michael J ^d  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e TUFTS MEDICAL CENTER   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^g MAYO CLINIC   (United States)

^h THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

c Kit; Carcinosarcoma; Imatinib; PDGFR; Uterus

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; STEM CELL FACTOR RECEPTOR;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER FATIGUE; CANCER GROWTH; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; EYE TOXICITY; FEMALE; HUMAN; HYPOCALCEMIA; IMMUNOHISTOCHEMISTRY; LYMPHATIC SYSTEM DISEASE; METABOLIC DISORDER; MULTICENTER STUDY; NAUSEA; NEPHROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; TREATMENT RESPONSE; UTERUS CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOSARCOMA; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; TREATMENT OUTCOME; UTERINE NEOPLASMS;

EID: 77950187254     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.01.002     Document Type: Article

References (42)

1. Olah K.S., Gee H., Blunt S., Dunn J.A., Kelly K., and Chan K.K. Retrospective analysis of 318 cases of uterine sarcoma. Eur. J. Cancer 27 (1991) 1095-1099
2. Zaloudek C.J., and Norris H.J. Mesenchymal tumors of the uterus. In: Fengolio C., and Wolff M. (Eds). Progress in Surgical Pathology vol. 3 (1981), Masson, New York 1-35
3. Spanos W.J., Peters L.J., and Oswald M.J. Patterns of recurrence in malignant mixed mullerian tumor of the uterus. Cancer 57 (1986) 155-159
4. Nordal R.R., and Thoresen S.O. Uterine sarcomas in Norway 1956-1992: incidence, survival, and mortality. Eur. J. Cancer 33 (1997) 907-911
5. Joensuu H., Roberts P., Sarlomo-Rikala M., Andersson L., Tervahartiala P., Tuveson D., et al. Effect of tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med. 344 (2001) 1052-1056
6. Sarlomo-Rikala M., Kovatich A.J., Barusevicius A., and Miettinen M. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod. Pathol. 11 (1998) 728-734
7. Blanke C., Von Mehren N., Joensuu H., Roberts P.L., et al. Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI-571, in patients with unresectable or metastatic gastrointestinal stromal tumors expressing c-kit (CD117). The American Society of Clinical Oncology Thirty-Seventh Annual Meeting. Abstract #1, San Francisco, CA (2001)
8. Van Oosterom A.T., Judson I., Verweij J., Stroobants S., Donato di Paola E., Dimitrijevic S., et al. Safety and efficacy of imatinib (STI-571) in metastatic gastrointestinal stromal tumor tumors: a Phase I study. Lancet 358 (2001) 1421-1423
9. Klein W.M., and Kurman R.J. Lack of expression of c-kit protein (CD117) in mesenchymal tumors of the uterus and ovary. Int. J. Gynecol. Pathol. 22 (2003) 181-184
10. Ramondetta L.M., Burke T.W., Jhingran A., Schmandt R., Bevers M.W., Wolf J.K., et al. A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed müllerian tumors with evaluation of potential molecular targets. Gynecol. Oncol. 90 (2003) 529-536
11. Winter III W.E., Seidman J.D., Krivak T.C., Chauhan S., Carlson J.W., Rose G.S., et al. Clinicopathological analysis of c-kit expression in carcinosarcomas and leiomyosarcomas of the uterine corpus. Gynecol. Oncol. 91 (2003) 3-8
12. Leath III C.A., Straughn Jr. J.M., Conner M.G., Barnes III M.N., Alvarez R.D., Partridge E.E., et al. Immunohistochemical evaluation of the c-kit proto-oncogene in sarcomas of the uterus: a case series. J. Reprod. Med. 49 (2004) 71-75
13. Menczer J., Kravtsov V., Levy T., Berger E., Glezerman M., and Avinoach I. Expression of c-kit in uterine carcinosarcoma. Gynecol. Oncol. 96 (2005) 210-215
14. Raspollini M.R., Susini T., Amunni G., Paglierani M., Taddei A., Marchionni M., et al. COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies?. Gynecol. Oncol. 96 (2005) 159-167
15. Rushing R.S., Shajahan S., Chendil D., Wilder J.L., Pulliam J., Lee E.Y., et al. Uterine sarcomas express KIT protein but lack mutation(s) in exon 11 or 17 of c-KIT. Gynecol. Oncol. 91 (2003) 9-14
16. Nakayama M., Mitsuhashi T., Shimizu Y., Ban S., Ogawa F., Ishihara O., et al. Immunohistochemical evaluation of KIT expression in sarcomas of the gynecologic region. Int. J. Gynecol. Pathol. 25 (2006) 70-76
17. Adams S.F., Hickson J.A., Hutto J.Y., Montag A.G., Lengyel E., and Yamada S.D. PDGFR-alpha as a potential therapeutic target in uterine sarcomas. Gynecol. Oncol. 104 (2007) 524-528
18. Erdogan G., Bassorgun C.I., Pestereli H.E., Simsek T., and Karaveli S. C-kit protein expression in uterine and ovarian mesenchymal tumours. APMIS 115 3 (2007) 204-209
19. Cimbaluk D., Rotmensch J., Scudiere J., Gown A., and Bitterman P. Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets. Gynecol. Oncol. 105 (2007) 138-144
20. Soslow R.A., Ali A., and Oliva E. Mullerian adenosarcomas: an immunophenotypic analysis of 35 cases. Am. J. Surg. Pathol. 32 (2008) 1013-1021
21. Sawada M., Tsuda H., Kimura M., Okamoto S., Kita T., Kasamatsu T., et al. Different expression patterns of KIT, EGFR, and HER-2 (c-erbB-2) oncoproteins between epithelial and mesenchymal components in uterine carcinosarcoma. Cancer Sci. 94 (2003) 986-991
22. Caudell J.J., Deavers M.T., Slomovitz B.M., Lu K.H., Broaddus R.R., Gershenson D.M., et al. Imatinib mesylate (Gleevec)-targeted kinases are expressed in uterine sarcomas. Appl. Immunohistochem. Mol. Morphol. 13 (2005) 167-170
23. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92 (2000) 205-216
24. Chen T.T., and Ng T.H. Optimal flexible designs in phase II clinical trials. Stat. Med. 17 (1998) 2301-2312
25. Trotti A., Colevas A.D., Setser A., Rusch V., Jaques D., Budach V., et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin. Radiat. Oncol. 13 (2003) 176-181
26. Agresti A. Analysis of Ordinal Categorical Data (1984), John Wiley & Sons, New York
27. 2 from contingency tables, and the calculation of P″. J. Royal Stat. Soc. 85 (1922) 87-94
28. Mehta C.R., and Patel N.R. A network algorithm for performing Fisher's exact test in r × c contingency tables. J. Am. Stat. Assoc. 78 (1983) 427-434
29. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53 (1958) 457-481
30. Mantel N., and Haenszel W. Statistical aspects of analysis of data from retrospective studies of disease. JNCI 22 (1959) 719-748
31. Cox D.R. Regression models and life tables. J. Royal Stat. Soc. 34 (1972) 187-220
32. Hollander M., and Wolfe D.A. Nonparametric Statistical Methods (1973), John Wiley & Sons, New York
33. Khalifeh I., Munkarah A.R., Schimp V., Morris R., Lawrence W.D., and Ali-Fehmi R. The impact of c-kit and ki-67 expression on patients prognosis in advanced ovarian serous carcinoma. Int. J. Gynecol. Pathol. 24 (2005) 228-234
34. Micke P., Basrai M., Faldum A., Bittinger F., Rönnstrand L., Blaukat A., et al. Characterization of c-kit expression in small cell lung cancer: prognostic and therapeutic implications. Clin. Cancer Res. 9 (2003) 188-194
35. Scobie J.V., Acs G., Bandera C.A., Blank S.V., Wheeler J.E., Pasha T.L., et al. C-kit immunoreactivity in endometrial adenocarcinomas and its clinicopathologic significance. Int. J. Gynecol. Pathol. 22 (2003) 149-155
36. López-Martin A., Ballestín C., Garcia-Carbonero R., Castaño A., Lopez-Ríos F., López-Encuentra A., et al. Prognostic value of KIT expression in small cell lung cancer. Lung. Cancer 56 (2007) 405-413
37. Wetli S.C., Leuschner I., Harms D., Rufle A., Foerster A., Bihl M., et al. KIT, PDGFRalpha and EGFR analysis in nephroblastoma. Virchows. Arch. 452 (2008) 637-650
38. Haberler C., Gelpi E., Marosi C., Rössler K., Birner P., Budka H., et al. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy. J. Neurooncol. 76 (2006) 105-109
39. Braconi C., Bracci R., and Cellerino R. Molecular targets in gastrointestinal stromal tumors (GIST) therapy. Curr. Cancer Drug Targets 8 (2008) 359-366
40. Roberts K.G., Odell A.F., Byrnes E.M., Baleato R.M., Griffith R., Lyons A.B., et al. Resistance to c-KIT kinase inhibitors conferred by V654A mutation. Mol. Cancer Ther. 6 (2007) 1159-1166
41. Miselli F.C., Casieri P., Negri T., Orsenigo M., Lagonigro M.S., Gronchi A., et al. c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors. Clin. Cancer Res. 13 (2007) 2369-2377
42. Wolfson A.H., Brady M.F., Rocereto T., Mannel R.S., Lee Y.C., Futoran R.J., et al. A Gynecologic Oncology Group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol. Oncol. 107 (2007) 177-185